CIK 0001799448
- Non-accelerated filer
- Smaller reporting company
Aligos Therapeutics, Inc.
Sign in to watch- Ticker
- ALGS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 800-466-6059
- Business address
- ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +72,000 | 72,000 | ||
| 2024-02-28 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +75,183 | 75,183 | ||
| 2024-02-28 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +65,713 | 65,713 | ||
| 2024-02-28 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +16,428 | 16,428 | ||
| 2024-02-27 | McClure Matthew W. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −255,626 | 0 | ||
| 2024-02-27 | McClure Matthew W. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −92,000 | 0 | ||
| 2024-02-27 | McClure Matthew W. Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −23,000 | 0 | ||
| 2023-09-08 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +48,000 | 48,000 | ||
| 2023-03-15 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-07-07 | McClure Matthew W. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +46,000 | 46,000 |
Page 1 of 1 · 10 trades